These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28747279)

  • 1. Portable objective assessment of upper extremity motor function in Parkinson's disease.
    Chahine LM; Uribe L; Hogarth P; McNames J; Siderowf A; Marek K; Jennings D
    Parkinsonism Relat Disord; 2017 Oct; 43():61-66. PubMed ID: 28747279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease.
    Haaxma CA; Bloem BR; Borm GF; Horstink MW
    Mov Disord; 2008 Sep; 23(12):1707-17. PubMed ID: 18649395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease.
    Lee W; Evans A; Williams DR
    J Parkinsons Dis; 2016 Apr; 6(2):371-82. PubMed ID: 27061062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
    Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
    J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
    Rodriguez-Blazquez C; Rojo-Abuin JM; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG; Martinez-Martin P
    Parkinsonism Relat Disord; 2013 Oct; 19(10):889-93. PubMed ID: 23791519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
    Simuni T; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun D; Poston K; Arnedo V; Frasier M; Sherer T; Chowdhury S; Marek K;
    Mov Disord; 2018 May; 33(5):771-782. PubMed ID: 29572948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication.
    Smits EJ; Tolonen AJ; Cluitmans L; van Gils M; Zietsma RC; Borgemeester RW; van Laar T; Maurits NM
    IEEE J Biomed Health Inform; 2017 Jan; 21(1):283-289. PubMed ID: 26625435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale.
    Martínez-Martín P; Rodríguez-Blázquez C; Mario Alvarez ; Arakaki T; Arillo VC; Chaná P; Fernández W; Garretto N; Martínez-Castrillo JC; Rodríguez-Violante M; Serrano-Dueñas M; Ballesteros D; Rojo-Abuin JM; Chaudhuri KR; Merello M
    Parkinsonism Relat Disord; 2015 Jan; 21(1):50-4. PubMed ID: 25466406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting outcomes in Parkinson's disease: comparison of simple motor performance measures and The Unified Parkinson's Disease Rating Scale-III.
    Grill S; Weuve J; Weisskopf MG
    J Parkinsons Dis; 2011; 1(3):287-98. PubMed ID: 23939309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
    He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
    J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity: The Mobile Parkinson Disease Score.
    Zhan A; Mohan S; Tarolli C; Schneider RB; Adams JL; Sharma S; Elson MJ; Spear KL; Glidden AM; Little MA; Terzis A; Dorsey ER; Saria S
    JAMA Neurol; 2018 Jul; 75(7):876-880. PubMed ID: 29582075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified conversion method for unified Parkinson's disease rating scale motor examinations.
    Hentz JG; Mehta SH; Shill HA; Driver-Dunckley E; Beach TG; Adler CH
    Mov Disord; 2015 Dec; 30(14):1967-70. PubMed ID: 26779608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.